ONC212 in Oncology

ONC212 is a highly selective agonist of the orphan GPCR, GPR132, which is a tumor suppressor. It exhibits broad-spectrum efficacy at nanomolar concentrations across solid tumors and hematological malignancies. ONC212 shows broad therapeutic potential in preclinical studies.

For more information on ONC212, please refer to our Publications and to the ‘Our Science’ section of our website.

Development of ONC212

Oncoceutics has entered an alliance agreement with the MD Anderson Cancer Center for Phase I and Phase II trials of ONC212 in patients with acute leukemias.

The United States Patent and Trademark Office (USPTO) has issued a patent providing the company with composition of matter protection for ONC212.